FDA orders eye-condition warning on all GLP-1 drugs, citing thin trial data
The November 9 safety notice rests on 15 probable cases across 126 trials and a real-world study whose results depend on the comparison drug. The FDA calls the risk potential.
By Eli Okafor, Health & Wellness
· 3 min read

On November 9, the FDA required every GLP-1 receptor agonist label in the United States to carry a warning about non-arteritic anterior ischemic optic neuropathy, or NAION, a sudden and usually permanent loss of vision in one eye. The agency calls the risk potential. The evidence behind the change is real but thin.
The bottom line
The FDA ordered a NAION warning on all GLP-1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, on November 9, 2026. Across 126 trials, NAION occurred at 6.4 per 100,000 person-years on GLP-1 drugs versus 3.8 on comparators, based on 15 total cases. A real-world study found no significant increase against one drug class and a higher risk against another.
What the trial numbers show
The FDA pooled 126 randomized trials covering 134,253 participants and 288,879 person-years. It counted 15 probable NAION events. Ten were in people taking GLP-1 drugs, five were in people on placebo, and none were in people on other glucose-lowering drugs. That works out to 6.4 cases per 100,000 person-years on GLP-1 drugs and 3.8 on comparators.
Fifteen events is a small base for any rate. Pharmacy Times, which covered the notice in detail, pointed to the same limit, and the agency's own wording is that the risk is potential. The evidence is thin.
Real-world data points two ways
The agency also ran a Sentinel study of adults with type 2 diabetes who started treatment between 2019 and 2024. NAION rates were 30 to 32 per 100,000 person-years for GLP-1 drugs, 31 for SGLT-2 inhibitors and 26 for DPP-4 inhibitors. Against SGLT-2 inhibitors, the hazard ratio was 1.19, with a confidence interval of 0.91 to 1.54, which includes no difference. Against DPP-4 inhibitors it was 1.43, with an interval of 1.02 to 2.01, which does not.
The trigger was a July 2024 JAMA Ophthalmology study led by Hathaway, drawn from patients seen by neuro-ophthalmologists at a single academic institution. It reported hazard ratios of 4.28 for people with type 2 diabetes and 7.64 for people with overweight or obesity who took semaglutide. The FDA identified several limitations in that study, and its ratios are far larger than the differences in the agency's later analyses.
“The medicines have really been profoundly beneficial to a large number of people.”
What clinicians and patients are told
Rizzo told CBS News he believes the evidence shows GLP-1 use raises NAION risk, and he does not discourage patients from taking the drugs. He said the vision loss is usually irreversible and can worsen even after the medication is stopped. On prevention he was direct: "we do not really know how to mitigate the risk."
The FDA notice tells clinicians to refer suspected cases to an ophthalmologist promptly and to consider discontinuing the drug in a patient who develops NAION, unless the benefits clearly outweigh the risk. Patients with a prior NAION event are directed to discuss continuing with their clinician. The agency lists known risk factors as smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease. Pharmacy Times noted that this overlaps with conditions common in people prescribed these drugs, which makes adverse event reports hard to interpret.
The base rate and the manufacturers
The FDA puts background NAION incidence in adults over 50 at 2.3 to 10.2 cases per 100,000 people a year. Both trial rates, 6.4 and 3.8, fall inside that range.
Novo Nordisk, which makes Ozempic and Wegovy, said it "continues to believe the data do not establish a cause-and-effect relationship." Eli Lilly, which makes Mounjaro and Zepbound, said it was "carefully evaluating the update" and noted that the communication covers the whole class without findings specific to its products.
The label change reaches every product the FDA lists, from generic exenatide to Foundayo (orforglipron), approved this year. The agency lists the symptoms that should prompt immediate care: sudden painless vision loss in one eye, blind spots, tunnel vision, color distortion, or blurry or hazy central vision.
Sources
- 01FDA Drug Safety Communication: safety labeling changes for GLP-1 RAs and a rare eye condition, U.S. Food and Drug Administrationfda.gov
- 02FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk, Pharmacy Timespharmacytimes.com
- 03GLP-1 drugs get FDA warning of rare vision-loss side effect, CBS Newscbsnews.com
Corrections
No corrections have been made to this article.
About the reporter
Health & Wellness Reporter, Trestlewire
I am not a physician, and nothing I write is medical advice. I say that first because it shapes everything else.
Read full bio and all stories →The Morning Wire
The day’s reporting, in your inbox before nine.
Free. Unsubscribe any time. We never share your address.
